<DOC>
	<DOCNO>NCT00024284</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness combine carboplatin irinotecan treat child refractory solid tumor .</brief_summary>
	<brief_title>Carboplatin Irinotecan Treating Children With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose carboplatin irinotecan child refractory solid tumor . - Determine safety profile dose-limiting toxic effect regimen patient . - Determine pharmacokinetics regimen patient . - Determine preliminary anti-tumor activity regimen patient . OUTLINE : This dose-escalation study carboplatin irinotecan . Patients receive carboplatin IV 50 minute day 1 irinotecan IV 1 hour day 1-5 8-12 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carboplatin irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow least 30 day . PROJECTED ACCRUAL : A total 25-30 patient accrue study within 6-9 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor , include primary brain tumor Progressive disease standard therapy standard therapy exist No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Lansky 50100 % ( age 10 ) Karnofsky 50100 % ( age 10 ) Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL ALT great 2.5 time upper limit normal Renal : Glomerular filtration rate least 30 mL/min Other : No active infection No serious uncontrolled medical disorder No psychiatric disorder disorder would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior allogeneic bone marrow transplantation without evidence acute chronic graft versus host disease At least 3 month since prior autologous bone marrow peripheral blood stem cell transplantation At least 4 week since prior immunotherapy recover No concurrent immunotherapy Chemotherapy : No 3 prior chemotherapy regimen At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : Concurrent hormone replacement therapy oral contraceptive allow No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy ( include brain metastasis ) recover No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational anticancer drug No concurrent antitumor therapy No concurrent anticonvulsant ( e.g. , phenytoin , phenobarbital , carbamazepine ) except gabapentin ( Neurontin )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>